Herd immunity induced by COVID-19 vaccination programs to suppress epidemics caused by SARS-CoV-2 wild type and variants in China

Hengcong Liu[1]*, Juanjuan Zhang [1,2]*, Jun Cai[1], Xiaowei Deng[1], Cheng Peng[1], Xinghui Chen[1], Juan Yang[1,2,3], Qianhui Wu[1], Zhiyuan Chen[1], Wen Zheng[1], Cécile Viboud[4], Wenhong Zhang[1]†, Marco Ajelli[5,6]† and Hongjie Yu[1,2,3]†

1. Department of Infectious Diseases, Huashan Hospital, School of Public Health, Fudan University, Shanghai, China

2. Key Laboratory of Public Health Safety, Fudan University, Ministry of Education, Shanghai, China

3. Shanghai Institute of Infectious Disease and Biosecurity, Fudan University, Shanghai, China

4. Division of International Epidemiology and Population Studies, Fogarty International Center, National Institutes of Health, Bethesda, MD, USA

5. Department of Epidemiology and Biostatistics, Indiana University School of Public Health, Bloomington, IN, USA

6. Laboratory for the Modeling of Biological and Socio-technical Systems, Northeastern University, Boston, MA, USA

*These authors contributed equally to this work.

†These authors are joint senior authors contributed equally to this work.

Corresponding authors: Hongjie Yu, Shanghai Institute of Infectious Disease and

Biosecurity, School of Public Health, Fudan University, Shanghai 200032, China

E-mail: yhj@fudan.edu.cn

Word count (main text): 3,791

Word count (abstract): 212

Abstract

To allow a return to a pre-COVID-19 lifestyle, virtually every country has initiated a

vaccination program to mitigate severe disease burden and control transmission; over

3.6 billion vaccine doses have been administered as of July 2021. However, it remains

to be seen whether herd immunity will be within reach of these programs, especially

as more transmissible SARS-CoV-2 variants continue to emerge. To address this

question, we developed a data-driven model of SARS-CoV-2 transmission for

Shanghai, China, a population with low prior immunity from natural infection. We

found that extending the vaccination program to individuals aged 3-17 years plays a

key role to reach herd immunity for the original SARS-CoV-2 lineages. With a

vaccine efficacy 74% against infection, vaccine-induced herd immunity would require

coverages of 93% or higher. Herd immunity for new variants, such as Alpha or Delta,

can only be achieved with more efficacious vaccines and coverages above 80-90%. A

continuation of the current pace of vaccination in China would reach 72% coverage

by September 2021; although this program would fail to reach herd immunity it

would reduce deaths by 95-100% in case of an outbreak. Efforts should be taken to

increase population's confidence and willingness to be vaccinated and to guarantee

highly efficacious vaccines against more transmissible variants of concern.

Introduction

The first-wave of novel coronavirus disease 2019 (COVID-19) in China subsided

quickly after the implementation of strict containment measures and travel restrictions

starting in March 2020 [1]. As of July 21, 2021, the COVID-19 pandemic has caused

over 191 million reported cases and 4.1 million deaths globally [2]. The pandemic is far

from over, as SARS-CoV-2 has undergone some significant mutations and a number

of variants have become widespread due to increased transmissibility and/or immune

escape characteristics – e.g., variants Alpha [3-5], Beta [6], Gamma [7], and Delta [8]. After

the original COVID-19 wave in early 2020, China has experienced several minor

local outbreaks [9], including one detected in June 2021 in Guangdong Province caused

by imported cases of Delta variant from India [10]. To control this pandemic, a large

share of the world needs to have immunity to SARS-CoV-2.

Effective vaccines against COVID-19 represent the most viable option to suppress

SARS-CoV-2 transmission globally. The effectiveness of vaccination programs

depends on several key factors, including vaccine supply, willingness to receive the

vaccine, vaccine efficacy, and the age groups targeted by the vaccination effort. In

China, home of about 1.4 billion people (~18% of the world population), 1.5 billion

doses have been administered as of July 20, 2021 [11]. This figure corresponds to 52.7%

of the whole population and 68.6% of the target population (i.e., individuals aged 18

years and above). However, it remains to be seen if and when the vaccine coverage

may reach a level sufficient to achieve herd immunity. Countries around the globe are

facing the same question.

The classical herd immunity level is defined as $1-1/R_0$, where R_0 is the basic

reproduction number – the average number of infections generated by a typical

infectious individual in a fully susceptible population [12]. For a vaccine with efficacy

VE that gives life-long protection, the level of herd immunity required to stop

transmission is $(1-1/R_0)$/VE. However, this estimate is an oversimplification of a

complex phenomenon as it ignores the heterogeneities of actual human population

(e.g., social mixing patterns, age-specific susceptibility to infection) [13,14] as well as of

vaccination (e.g., lifelong immunity, sterilizing vaccine). To overcome this limitation,

here we integrate contact survey data collected in Shanghai, China [15] as well as

official demographic statistics of the Shanghai population, and develop an age-

structured stochastic model to simulate SARS-CoV-2 transmission triggered by case

importation (Fig.S1 in *SI Appendix*). We then use this model to evaluate whether herd

immunity is achievable or not via mass vaccination and to explore the way forward to

achieve suppression of SARS-CoV-2 transmission.

Results

Modeling SARS-CoV-2 transmission and vaccination

In the susceptible-infectious-removed SIR transmission model, we account for

Shanghai-specific age structure, heterogeneous mixing patterns by age, and

heterogeneous susceptibility to infection by age. The number of symptomatic cases,

hospitalizations, ICU admissions, and deaths are then derived from estimated number

of infections. A qualitative model description is reported in the Methods section, a

summary of model parameters, and data sources is reported in *SI Appendix* Table S1.

The model allows the explicit simulation of the vaccination strategy currently used in China: random distribution of vaccines to adults aged 18+ years (strategy 1). Two of the SARS-CoV-2 vaccines (i.e., CoronaVac and BBIBP-Corv) used in China have been licensed for children aged 3 to 17 years [16]; however, as of July 21, 2021 children are not included among the target population for vaccination. To explore the contribution of vaccinating children aged 3-17 years to achieving herd immunity, we test two alternative strategies: i) same as strategy 1, but extended to individuals aged 3+ years starting from September 1, 2021 (strategy 2); ii) random distribution of vaccines to individuals aged 3+ years since the start of vaccination programs (strategy 3).

All individuals with vaccine contraindications or pregnant women (2.15% of the population) are excluded from the target population of the focus vaccination programs (see Sec. 4 of *SI Appendix* for details). The vaccine schedule requires two doses and VE is set at 73.5% against infection, in line with clinical trial data [17]. In the baseline scenario, we assume that forty infected individuals [18] are introduced in the population on September 1, 2021, and R_0=2.5 in the absence of interventions, as estimated for the historical SARS-CoV-2 lineage in China [19-22]. This is an optimistic scenario for SARS-CoV-2 transmission in 2021; however we also present simulations corresponding to highly transmissible variants currently circulating globally, with R0 up to 6. We do not assume any social distancing in the main scenario, although we run sensitivity analyses with different levels of non-pharmaceutical interventions (NPIs).

The proportion of the population immune from natural infection is considered near

0% at the start of simulations. The number of vaccine doses administered per day

(vaccination capacity) exponentially increases and is capped at 1.22% of the

population (see Sec. 5 of *SI Appendix* for details). As of September 1, 2021, the

projected vaccination coverage is 71.2% of the population (Fig.1A-C).

Baseline scenario

By forward simulating one year and assuming no vaccine hesitancy, continued

vaccination efforts lead to a final coverage of 97.6% of the target population, which

corresponds to 86.4% of the total population for strategy 1 and 95.6% for strategies 2

and 3 (Fig. 1A-C). Under any scenario, the mean incidence of newly infected

individuals never reaches 20 over 10,000 residents (Fig. 1D-F). We estimated the

impact of vaccination on reproduction number by using the next-generation matrix

approach [23] (see Sec. 2-3 of *SI Appendix* for details). We estimated that the effective

reproduction number at the time the infection is seeded (R_e) is still well above the

epidemic threshold, namely 1.72 (95%CI: 1.37-2.13), 1.73 (95%CI: 1.44-2.06), and

1.18 (95%CI: 1.17-1.19) for strategy 1-3, respectively. These estimates suggest that

the vaccine coverage on September 1, 2021 is not enough to prevent onward

transmission, regardless of the vaccination strategy. R_e is estimated to cross the

epidemic threshold (i.e., 1) on January 22, 2022, October 6, 2021 and September 16,

2021 for strategy 1, 2, and 3, respectively (Fig. 1G-I). Compared with strategy 1, with

an infection attack rate of 5.54% (95%CI: 2.35-7.78%), strategy 2 and 3 are

associated with infection attack rates lower than 4 per 100,000 (Fig.1J-L).

Although vaccine-induced immunity is not enough to prevent viral circulation, all the

scenarios considered are associated with substantial mitigation of COVID-19 burden.

We estimate the infection attack rate for the three vaccination strategies to decrease by

more than 90% with respect to a reference scenario with no interventions, with

cumulative infection attack rates in the range of 554 to 0.12 per 10,000 individuals.

Strategy 2-3 achieve the highest reduction (close to 100%) thanks to the inclusion of

the age group 3-17 years in the target population of the vaccination program (Fig. 2A-

B). Similar reductions are obtained also for other metrics of COVID-19 burden (e.g.,

hospitalized cases, individuals requiring an ICU; see Fig. S3 in *SI Appendix*). Nearly

no difference in the reduction of overall number of deaths is observed among the three

strategies (reduction close to 100%), with cumulative number of deaths no larger than

1 per 10,000 individuals. This pattern is explained by the substantially lower case

fatality ratio in individuals 0-17 years (0.51%) compared to other age groups (Fig.

2C-D) [24].

These results were based on the assumption of an "all-or-nothing" vaccine (i.e., a

vaccinated individual will either develop full protection with probability given by the

vaccine efficacy or zero protection). To test the robustness of our findings to this

assumption, we also tested a "leaky" vaccine (i.e., the susceptibility to infection of

any vaccinated individual is reduced by a factor equal to the vaccine efficacy [25]) and

we obtained very consistent results with respect to the baseline analysis (Fig. S4 in *SI Appendix*). Moreover, the obtained results are confirmed when the initial number of seeds is varied in the range from 10 to 100 (Fig. S5 in *SI Appendix*), and when equal susceptibility to infection by age is assumed (Fig. S6 in *SI Appendix*). Finally, we also conducted a counterfactual analysis where we assume that a part of the population was already immune before the start of the vaccination campaign (similar to the situation in Western countries). Under this assumption, we found that a 10% initial immunity proportion would lead to R_e below the epidemic threshold for strategy 3 before September 1, the start date of the simulations (Fig. S7 in *SI Appendix*).

As regard the parameters regulating the vaccination process, we found that the (overall) vaccine efficacy has the largest impact, followed by the vaccine efficacy of individuals aged 3-17 and 60+ relative to individuals aged 18-59 years (Fig. S8 and S9 in *SI Appendix*). On the other hand, the time between vaccination and maximum protection and the time interval between the first and second dose have a more moderate impact on the overall effectiveness of the analyzed vaccination strategies (Fig. S10 and S11 in *SI Appendix*).

Scenario 1: Delaying the start of the epidemic

The findings presented thus far suggest that herd immunity cannot be built through vaccination by September 1, 2021. Next, we test to what extent the start of a new epidemic wave needs to be delayed (e.g., by keeping strict restriction for international

travels) to allow the immunity to build up in the population, potentially reaching herd

immunity levels. According to the daily vaccine capacity used in the baseline scenario

(based on the history of daily vaccination capacity data up to May 23, 2021), we

estimate that R_e remains above the epidemic threshold for strategy 1 even if the

epidemic is delayed to November 1, 2021 (Fig. 3A and Fig. S12 in *SI Appendix*).

However, simulation results show that for strategy 2 and 3 it is possible to decrease R_e

below the epidemic threshold when the epidemic start is delayed until after November

1, 2021- at that time, the vaccination coverage is estimated to reach 95.6%. In

addition, in this case, strategies 2 and 3 lead to a higher reduction of the infection

attack rate with respect to the scenario with no intervention (less than 0.4 per 100,000

individuals for an epidemic starting on November 1, 2021 - Fig. 3B-C). The estimated

cumulative number of deaths is estimated to be reduced by more than 95% (Fig. S13

in *SI Appendix*).

Scenario 2: Adopting NPIs in case of a new outbreak

The results presented so far suggest that herd immunity is not achievable at any time

point without targeting also individuals 17 years old or younger (strategy 1). Adopting

NPIs as a response to an epidemic outbreak can lower the transmission potential of

the virus. It is thus worth investigating the synergetic effect of vaccination programs

combined with NPIs of different intensity. It is important to note that we do not

explicitly model every single measure to limit transmission (e.g., case isolation,

contact tracing, wearing masks, social distancing, improved hygiene). These measures

are implicit as concerted strategies that result in a decreased reproduction number. We

define the value of the reproduction number in a fully susceptible population and

under a certain level of NPIs as R_0^{NPIs}. We explored R_0^{NPIs} in the range 1.1-2.3.

The reproduction number on September 1, 2021 for strategy 1 and 2 can be reduced to

below the epidemic threshold when R_0^{NPIs}=1.1 only, while strategy 3 can lead to a

drastic decrease in R_e, reaching herd immunity when R_0^{NPIs}<2.1 (Fig. 3D). By forward

vaccinating and simulating 1 year of epidemic, substantial infections could be reduced

thanks to the synergetic effect of vaccination and NPIs (Fig. 3E-F), with a reduction

of more than 95% of deaths as compared with no intervention scenario (Fig. S15 in *SI*

Appendix).

Scenario 3: Delaying the start of the epidemic and adopting NPIs

To further improve the potential for vaccination-induced herd immunity against the

SARS-CoV-2 and reduce COVID-19 burden, here we tested the combination of the

two scenarios mentioned above: delaying the start of the epidemic and adopting NPIs

of different level of intensity in response to a new outbreak.

Should an epidemic start in mid-September 2021, herd immunity would be achievable

only for strategy 3 (Fig. 4C). If the epidemic is further delayed to October 2021 and

moderate NPIs are adopted, strategy 2 can succeed in blocking transmission (Fig. 4B).

In the case of strategy 1 (i.e., the vaccination policy excluding underage individuals),

strict NPIs should be adopted to prevent a major epidemic wave (Fig. 4A and Fig.

S16-17 in *SI Appendix*).

Herd immunity threshold

We explored the vaccination-induced herd immunity threshold in the absence of

transmission by estimating R_e under different fixed vaccine coverage. We estimated

that R_e decreases below 1.0 only for strategy 2 and 3 (Fig. 5A). The estimated herd

immunity threshold under these two strategies is 92.8% and 80.8%, respectively,

which suggests that level of immunity needed to lead the effective reproduction

number below the epidemic threshold is lower if vaccination is extended to

individuals aged 3-17 years early on. In particular, we estimated that for strategy 2 the

required immunity level (92.8%) could be reached on October 5, 2021 (Fig.5B).

We also estimated the infection attack rate under different vaccination coverages

under the assumption that vaccination stops at the time the epidemic is seeded. This

purely hypothetical scenario shows that when the adult population (18+ years of age)

is vaccinated (strategy 1), despite a fairly high estimated reproduction number (1.68),

the estimated infection attack rate is relatively low (5.94%) (Fig. 5A and 5C). In fact,

given the age-targeted vaccination program and the lack of natural immunity, the

susceptible population is mostly concentrated in the young population. The high

number of contacts in younger age groups, combined with the high vaccination

coverage in the rest of the population, lead to a fairly high reproduction number but,

at the same time, the infections are focused on a small segment of the population only

(young individuals) and thus the overall infection attack rate remains fairly low.

The effectiveness of age-targeted vaccination strategies depend on the age-mixing

patterns of the population [26]. To test the robustness of our findings, we tested an

alternative contact matrix for China [27] and we found consistent results (Fig. S18-19 in

SI Appendix). In addition, to explore to what extent vaccine efficacy affects the herd

immunity threshold, we estimate R_e by increasing the efficacy against infection to

85% and 95%. Our results show that, although R_e decreases, the results for strategy 1

and 2 are rather consistent with those obtained in the main analysis (Fig. S20 in *SI*

Appendix). In contrast, for strategy 3 the threshold is estimated to be substantially

lower 63.0% in the case of a 95% efficacious vaccine (Fig. S20 in *SI Appendix*).

SARS-CoV-2 variants

Given the global epidemiological situation of COVID-19 as of July 2021, it is likely

that, should a major epidemic wave start to unfold in China, it will be caused by a

SARS-CoV-2 variant. Four SARS-CoV-2 variants of concern (Alpha, Beta, Gamma,

and Delta) are considered in our analysis, each of which is characterized by a specific

transmissibility (Tab. S2 in *SI Appendix*). Moreover, given the uncertainty

surrounding the estimates of vaccine efficacy against them, we explored VE in the

range 60-100%.

Our results show that, for any of these four variants, herd immunity is unattainable for

a vaccine with 73.5% efficacy as in the baseline scenario, even in the extreme case

where the vaccine coverage is 100% (Fig. 6). Vaccine-induced herd immunity may

only be achievable with higher VE and high coverage. For example, for a vaccine

with 90% efficacy against the Alpha variant, more than 83% of the population would

need to be vaccinated to reach herd immunity (Fig. 6). Similarly, for a vaccine 90%

efficacious against Delta, herd immunity would require more than 92% of the

population vaccinated (Fig. 6).

Discussion

Our study evaluates the feasibility of reaching herd immunity against SARS-CoV-2

through vaccination, considering heterogeneity in population age structure, age-

specific contact patterns, vaccine efficacy, as well as biological characteristics of the

historical SARS-CoV-2 lineages and variants. Our findings show the key role of

extending the vaccination program to school-aged children in order to reach herd

immunity. Considering the vaccination capacity in China in July 2021, an expansion

of vaccination program to the population aged 3 years or more would achieve herd

immunity against the original SARS-CoV-2 lineage by September, 2021. However,

herd immunity is unlikely to be reached against new variants of concern. If we

consider the transmissibility of the Delta variant, herd immunity would require

vaccination of 87.5% of the whole population with a highly efficacious vaccine

against infection (95% efficacy, which does not exist yet). The adoption of NPIs could

prevent the spread of a major epidemic wave even when the herd immunity level is

not reached, but such an option obviously entails social and economic costs. Further,

all strategies considered in this study would mitigate the overwhelming majority of

deaths.

Our study explored if and when vaccination-induced herd immunity can be reached in

China. Under the hypotheses that the circulating strain has the same transmissibility

as historical lineages and that the vaccination campaign will not slow down due to

vaccine hesitancy, for a strategy targeting adults first, followed by individuals aged 3-

17 years (strategy 2), herd immunity could be reached as early as mid-October 2021.

However, should the vaccination program target individuals aged 18 years or more

only (strategy 1), herd immunity seems to remain an unreachable target given that

about 14% of the Chinese population would be excluded from the program (either

because of age or other forms of non-eligibility). This finding is consistent with a

previous study reporting that herd immunity may only be possible if the vaccination

program is extended to children [28]. Nonetheless, it is important to remark that the

effectiveness of the vaccination program is impacted both by the natural immunity

accumulated in the population (which is close to 0 in China as of July 2021) and the

age structure of the population. In fact, in populations with a lower proportion of

children, herd immunity may be achievable through vaccination of adults only.

Our findings point to the importance of adopting NPIs and/or self-precautionary

measures until herd immunity is reached, or the burden of the epidemic becomes

manageable. These measures can either help delay the seeding of the infection (e.g.,

strict border control measures) or, should an epidemic start to unfold, to mitigate its

burden (e.g., social distancing, contact tracing, testing, wearing masks, hygiene

practices, limiting contacts). However, questions remain about which NPIs need to be

implement, their intensity, and timing. Future studies are needed to address these

questions.

A key role to determine whether herd immunity can be reached is played by the

willingness-to-vaccine of the population. According to previous surveys on COVID-

19 vaccine hesitancy, vaccine acceptance in China was estimated to vary between

60.4% and 91.3% for general population aged 18 years and above [29-32], and may be

even lower for older adults [32] and healthcare workers [33]. Similar estimates were

obtained for several other countries including the UK (71.5%) [34] and the US (75.4%)

[34]. Given these levels of vaccine hesitancy, achieving high levels of coverage may

remain an elusive target. Efforts to increase population's confidence and willingness

to be vaccinated will thus be of paramount importance to allow a return to a pre-

COVID-19 lifestyle. Our study shows that the spread of new more transmissible (and

possibly also more lethal [35-42]) variants substantially increases herd immunity

thresholds to level that may not be feasible in any population, so that mitigation

strategies become much more relevant.

Previous studies have estimated the herd immunity threshold either through natural

infection or vaccination under the assumption of an homogenously mixed population

[28,43-46], but heterogeneity in contact structure, age structure of the population,

susceptibility to infection by age, and order in which individuals are vaccinated are all

key factors shaping the herd immunity level [14,47,48] The developed model is based on

social mixing patterns estimated for the Shanghai population [15] and on China-specific

data on COVID-19 epidemiology (population immunity, hospitalization rates [24], case

fatality ratio [24], etc.). Nevertheless, the introduced modeling framework is flexible and

can be tailored to other countries We tested a scenario close to the situation in the

USA, where initial fraction of naturally immune population is set to 22% [49] and a

BNT162b2/Pfizer vaccine with 95% VE [50] is considered. The results show that the

initial (natural) immunity level in the population and the use of a more efficacious

vaccine may theoretically ease the path towards reaching herd immunity (Fig. S21 in

SI Appendix), although the spread of the Delta variant may counterbalance these

effects making it virtually impossible to reach herd immunity. Moreover, vaccination

hesitancy may jeopardize the vaccination effort in the US and other Western countries

as well.

This study is prone to the limitations pertaining to modeling exercises. First, VE for

children have not been estimated for the vaccines in use in China; therefore, we have

assumed the same VE as in adults based on immunogenicity studies [51]. Given such a

lack of field evidence, we have conducted a sensitivity analysis where a lower vaccine

efficacy is assumed for children. The overall conclusions of the study do not change.

Still, further data on age-specific vaccine efficacy could help refine the obtained

estimates.

Second, we assumed that immunity induced either from infection or vaccination lasts

more than the time horizon considered in the simulations (i.e., 1 year). There are both

evidence from laboratory studies and the field suggesting that the protection lasts

several months [52-54]. Despite these preliminary pieces of evidence, the duration of the

immunity remains a research area of paramount importance and intrinsically linked to

viral evolution. It is also possible that waning immunity will continue to provide

protection against severe disease but only partial against infection or transmission,

which affects the herd immunity threshold. Overall, the duration and quality of

immunity will determine the periodicity of COVID-19 outbreaks globally [55,56].

Third, in the baseline scenario, we referred to an inactivated SARS-CoV-2 vaccine

(BBIBP-CorV) taken to be 73.5% efficacious against infection [17]. However, several

other vaccines (including CoronaVac, WBIP-CorV, Ad5 nCoV, and ZF2001) are

licensed and have been used in China [57-60]. We varied vaccine efficacy in the range

60%-84% in sensitivity analyses. The main conclusion about the need to extend the

vaccination campaign to children is unaltered.

In conclusion, based on the current evidence, reaching vaccine-induced herd

immunity in a population with little/no natural immunity is challenging. Key steps

will be the authorization of COVID-19 vaccines for children and minimize vaccine

hesitancy. These, together with highly efficacious vaccines, will be even more crucial

given the global spread of SARS-CoV-2 variants with higher transmission potential

than the historical lineages. Importantly, even if herd immunity is unlikely to be

reached, vaccination will still dramatically reduce COVID-19 burden.

Figures

Figure 1. Time series of vaccine coverage, daily incidence of new SARS-CoV-2

infections, effective reproductive number, R_e, and fraction of immune population.

A Age-specific vaccine coverage over time for strategy 1. Vaccination program is

assumed to be initiated on November 30, 2020 (i.e., the time that the vaccine doses

administrated was first officially reported in China). The dotted lines correspond the

start of epidemic. The inserted table shows the age-specific coverage for the two key

time points (the start of epidemic (i.e., September 1, 2021), and the time that the

coverage keeps constant (i.e., September 24), respectively). The line corresponds to

the mean value, while the shaded area represents 95% quantile intervals (CI). **B** As A,

but for strategy 2. **C** As A, but for strategy 3. **D** Daily incidence of new SARS-CoV-2

infections per 10,000 individuals for strategy 1 (mean and 95% CI). **E** As D, but for

strategy 2. **F** As D, but for strategy 3. **G** Effective reproduction number R_e over time

(mean and 95% CI), as estimated using the Next-Generation matrix method from the

time series of susceptible individuals for strategy 1. The shaded area in gray indicates

the epidemic threshold $R_e =1$. The numbers around the x-axis indicate when R_e cross

this threshold (i.e., January 22) for strategy 1. **H** As G, but for strategy 2. **I** As G, but

for strategy 3. **J** Proportion of immune population due to either natural infection or

vaccination over time for strategy 1. **K** As J, but for strategy 2. **L** As J, but for

strategy 3.

Figure 2. Burden of COVID-19 in the baseline scenario. A Cumulative number of

infections per 10,000 individuals after 1 simulated year for *reference scenario* and

three vaccination strategies (mean and 95% CI). *Reference scenario* indicates no

vaccination and no NPIs with R_0=2.5 at the beginning of transmission. Infections

consist of unvaccinated and vaccinated individuals. The bar corresponds to the mean

value, while the vertical line represents 95% quantile intervals. **B** Reduction in

infections (mean and 95% CI) with respect to the *reference scenario* in different age

groups and the total population. The reduction is defined as the estimated number of

infections after 1 year since the introduction of the initial infected individuals under

reference scenario minus the one under the vaccination strategy, relative to the

estimated number under *reference scenario*. The 95% CI of the reduction may cross 0

as the burden between reference scenario and vaccination scenario is approximately

the same in some simulations. We thus trimmed the lower limit of 95% CI at 0

through the manuscript. **C** As A, but for cumulative number of deaths. **D** As B, but for

reduction in deaths.

Figure 3. Impact of delaying the start of the epidemic and adopting NPIs. A

Estimated effective reproduction number (R_e, mean and 95% CI) as a function of

vaccine coverage at the time the infection is seeded (i.e., September 1, October 1 and

November 1). Colors refer to the scenario of delaying the start of the epidemic to

different date. The shaded area in gray indicates the herd immunity threshold R_e =1. **B**

Cumulative number of infections per 10,000 individuals after 1 simulated year for

reference scenario and three vaccination strategies (mean and 95% CI). *Reference*

scenario indicates no vaccination and no NPIs with R_0=2.5 at the beginning of

transmission. **C** Reduction in infections (mean and 95% CI) with respect to the

reference scenario. **D** As A, but for the scenario of adopting different intensity of

NPIs, R_0^{NPIs}. **E** As B, but for the scenario of adopting different intensity of NPIs. **F** As

C, but for the scenario of adopting different intensity of NPIs.

Figure 4. Impact of delaying the start of the epidemic start and adopting NPIs on estimated effective reproduction number R_e. A Estimated effective reproduction number (R_e) as a function of R_0^{NPIs} and epidemic start date for strategy 1. The bold line in black indicates the herd immunity threshold $R_e = 1$. **B** As A, but for strategy 2. **C** As A, but for strategy 3.

Figure 5. Effective reproduction number (R_e) and infection attack rate. A

Estimated effective reproduction number (R_e, mean and 95% CI) as a function of

vaccine coverage in the absence of transmission. Colors refer to three vaccination

strategies. The shaded area in gray indicates the herd immunity threshold R_e =1. The

numbers around the line indicate where R_e cross this threshold. **B** Age-specific

vaccine coverage over time for strategy 2 in the absence of transmission. The crossed

point of two dotted lines corresponds to the time the coverage reached the herd

immunity threshold. **C** The infection attack rate after 1 simulated year as a function of

vaccine coverage. The transmission is simulated with the initial vaccine coverage and

there is no longer vaccination after the infection is seeded.

Figure 6. The impact of vaccine efficacy and vaccine coverage on estimated effective reproduction number R_e. **A** for Alpha strain with R_0=4.0. **B** As A, but for Beta strain with R_0=3.8. **C** As A, but for Gamma strain with R_0=5.0. **D** As A, but for Delta strain with R_0=6.0. The bold line in black indicates the herd immunity threshold R_e =1. R_e is estimated in the scenario that all individuals are eligible to vaccination and vaccinated 2 doses before the epidemic starts.

Methods

SARS-CoV-2 transmission and vaccination model

We built a compartmental model of SRAS-CoV-2 transmission and vaccination, based on an age-structured stochastic SIR scheme, accounting for heterogeneous contact patterns by age as estimated in Shanghai [15] and heterogeneous susceptibility to infection by age as estimated using contact tracing data in Hunan province of China [61]. In the model, the population is divided into three epidemiological categories: susceptible, infectious, and removed, stratified by 17 age groups. Susceptible individuals can become infectious after contact with an infectious individual according to the age-specific force of infection. The rate at which contacts occur is determined by the mixing patterns of each age group. The average generation time was set to 7 days [61]. We consider a basic reproductive number (R_0) of 2.5 according to estimates for the historical SARS-CoV-2 lineages in China [19-21,62]. Higher values (in the range 3.8-6) are used when other variants of concern are modeled [35-42]. Simulations are initiated with 40 infectious individuals, corresponding to the number of cases first detected in a local outbreak in Beijing on June 11, 2020 [63].

We consider a 2-dose vaccine, that only susceptible individuals are eligible for vaccination (we recall that natural immunity is close to 0 in China as of July 2021), and that the duration of vaccine-induced immunity lasts longer than the time horizon considered in this study (i.e., 1 year). Details about the model are reported in Sec. 1 of *SI Appendix*.

Baseline vaccination scenario

As the baseline scenario, we considered the following assumptions:

i)   **Epidemic start**: An epidemic is assumed to be triggered by forty SARS-CoV-2 infections on September 1, 2021; vaccines have been rolling out in China since November 30, 2020 [64].

ii) **Vaccination strategy:** We test three different vaccination strategies:

   a)   Strategy 1—random distribution of vaccines to adults aged 18+ years

   b)   Strategy 2—same as strategy 1, but the vaccination is extended to individuals aged 3+ years starting from September 1, 2021

   c)   Strategy 3—random distribution of vaccines to individuals aged 3+ years since the start of the vaccination program.

   Note that in all scenarios, we consider that a fraction of the population (about 2% - Sec. 4 of *SI Appendix*) is not eligible to receive the vaccine (e.g., pregnant women, individuals with allergies or other conditions preventing them to safely receive the vaccine).

iii) **Vaccine capacity**: We simulated the daily vaccine administration capacity based on the vaccine capacity data throughout the entire vaccination campaign in China [65]. We found that the daily vaccine administration capacity exponentially increased during the initial phase of the campaign before stabilizing at 294,234 doses per day on June 2, 2021 for the Shanghai population (about 24 million individuals; details are reported in Sec. 5 of *SI Appendix*).

iv)   **Vaccine efficacy (VE)**: There are three types of COVID-19 vaccines currently

used in China: inactivated, recombinant protein subunit, and adenovirus-

vectored vaccines. Their VE was estimated to vary from 65% to 84%, except

for the one tested in Brazil (VE=50%) where Gamma variant was dominant at

the time of the trial [66-71]. We assume 73.5% VE against infection for a two-

dose schedule (with a 21-day interval) [17] and explore 60%-84% VE as

sensitivity analysis. We also test a two-dose schedule with a 14-day interval.

In addition, COVID-19 vaccines may not be equally effective across age

groups in preventing infection or disease. To understand the impact of this

assumption, we also tested a relative VE of 50% and 75% for individuals aged

3-17 and 60+ years as compared to VE for individuals aged 18-59 years.

v)   **Vaccine action**: We considered two ways in which VE could be below 100%:

an "all-or-nothing" vaccine (baseline analysis), in which the vaccine provides

full protection to a fraction VE of individuals who are vaccinated and no

protection to the remaining 1-VE vaccinated individual. The second option we

considered is a "leaky" vaccine in which all vaccinated individuals have a

certain level of protection to the infection corresponding to VE.

vi)   **Initial immunity**: As of July 2021, there is essentially no population

immunity from natural infection in China [72]. For the sake of generalizability of

results to other countries with ongoing transmission, we have explored a

scenario where 30% of the population has initial natural immunity [49].

vii) **Susceptibility to infection by age**: Children under 15 years of age were

estimated to have a lower susceptibility to SARS-CoV-2 infection as

compared to adults (i.e., individuals aged 15 to 64 years), while individuals

aged 65+ years had the highest susceptibility to infection [61].

viii) **Immunity duration**: We let the transmission model run for one year,

assuming a life-long protection from natural infection or vaccination.

Comprehensive sensitivity analyses to evaluate the impact of the baseline assumptions

on our results are carried out as well (Tab. S1 in *SI Appendix*).

Alternative vaccination scenarios

We test three alternative scenarios to explore the potential for vaccination-induced

herd immunity, where: i) epidemic start is delayed from September 1, 2021 to October

1, 2021, and November 1, 2021; ii) the initial reproduction number varies between 1.1

and 2.3 to account for different intensity of NPIs (R_0^{NPIs}); iii) combinations of scenarios

i and ii.

SARS-CoV-2 variants

Multiple SARS-CoV-2 variants have been documented globally, four of which are of

particular concern: Alpha, Beta, Gamma, and Delta [73]. These variants are estimated to

have higher transmissibility [3,6,8,42] and possibly an increased mortality [74,75]. To assess

the potential for herd immunity in this context, we consider a R_0 in the range 3.8-6

(Tab. S2 in *SI Appendix*).

Data analysis

For each scenario, 100 stochastic simulations were performed. The output of these

simulations determined the distribution of the number of infections. We then analyzed

model outcome to estimate the number of symptomatic infections, hospitalizations,

ICU admissions, and deaths by accounting for the transition probability between

different endpoints (Tab. S1 in *SI Appendix*). For vaccinated individuals, the estimates

of disease burden also account for estimates of vaccine efficacy against different

clinical endpoints (e.g., symptomatic case, hospitalization, ICU admission, death).

Details are reported in Sec. 1 in *SI Appendix*. We defined 95% credible intervals as

quantiles 0.025 and 0.975 of the estimated distributions.

We used the next-generation matrix approach to estimate the reproduction number, R_e.

Herd immunity is considered as achievable when $R_e < 1$. Details are reported in Sec. 2-

3 in *SI Appendix*.

Reference

Chinese Center for Disease Control and Prevention. *Update on COVID-19 as of 24:00 on May 30, 2021*, <http://2019ncov.chinacdc.cn/2019-nCoV/> (2021).

World Health Organization. COVID-19 Weekly Epidemiological Update. (2021).

Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. *Science*, eabg3055 (2021).

Gaymard, A. *et al.* Early assessment of diffusion and possible expansion of SARS-CoV-2 Lineage 20I/501Y.V1 (B.1.1.7, variant of concern 202012/01) in France, January to March 2021. *Euro Surveill* **26**, doi:10.2807/1560-7917.Es.2021.26.9.2100133 (2021).

Washington, N. L. *et al.* Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the United States. *Cell* (2021).

CMMID. Estimates of severity and transmissibility of novel South Africa SARS-CoV-2 variant 501Y.V2. (2021).

Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science*, eabh2644, doi:10.1126/science.abh2644 (2021).

Goverment, U. *SPI-M-O: Consensus Statement on COVID-19*, <https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/986709/S1237_SPI-M-O_Consensus_Statement.pdf> (2021).

Li, Z. *et al.* Comprehensive large-scale nucleic acid–testing strategies support China's sustained containment of COVID-19. *Nature Medicine* **27**, 740-742, doi:10.1038/s41591-021-01308-7 (2021).

The Paper News. *Outbreak of COVID-19 in Guangzhou city, China, caused by SARS-CoV-2 variant detected in India*, <https://www.thepaper.cn/newsDetail_forward_12897889> (2021).

National Health Commission of the People's Republic of China. *Update on COVID-19 vaccination in China*, <http://www.nhc.gov.cn/xcs/yqjzqk/202106/67dc906521854d33966e55e222a60941.shtml> (2021).

Diekmann, O., Heesterbeek, H. & Britton, T. *Mathematical Tools for Understanding Infectious Disease Dynamics*.   (Princeton University Press, 2013).

May, R. M. & Anderson, R. M. Spatial heterogeneity and the design of immunization programs. *Mathematical Biosciences* **72**, 83-111, doi:https://doi.org/10.1016/0025-5564(84)90063-4 (1984).

Britton, T., Ball, F. & Trapman, P. A mathematical model reveals the influence of population heterogeneity on herd immunity to SARS-CoV-2. *Science* **369**, 846-849, doi:10.1126/science.abc6810 (2020).

Zhang, J. *et al.* Patterns of human social contact and contact with animals in Shanghai, China. *Sci. Rep.* **9**, 15141, doi:10.1038/s41598-019-51609-8 (2019).

The State Council Information Office, P. R. C. *BBIBP-Corv and CoronaVac are extended to children aged 3-17 years*, <http://www.gov.cn/xinwen/gwylflkjz160/index.htm> (2021).

Al Kaabi, N. *et al.* Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. *JAMA*, doi:10.1001/jama.2021.8565 (2021).

18   Xinhua Net. *The COVID-19 outbreak in Beijing*,
<http://www.xinhuanet.com/politics/2020-06/19/c_1126135352.htm> (2020).

19   Pan, A. *et al.* Association of Public Health Interventions With the Epidemiology of the
COVID-19 Outbreak in Wuhan, China. *JAMA* **323**, 1915-1923,
doi:10.1001/jama.2020.6130 (2020).

20   Wu, J. T., Leung, K. & Leung, G. M. Nowcasting and forecasting the potential domestic
and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a
modelling study. *Lancet* **395**, 689-697, doi:10.1016/S0140-6736(20)30260-9 (2020).

21   Li, Q. *et al.* Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected
Pneumonia. *N Engl J Med* **382**, 1199-1207, doi:10.1056/NEJMoa2001316 (2020).

22   Chinazzi, M. *et al.* The effect of travel restrictions on the spread of the 2019 novel
coronavirus (COVID-19) outbreak. *Science* **368**, 395-400, doi:10.1126/science.aba9757
(2020).

23   Diekmann, O. & Metz, J. A. J. On the definition and the computation of the basic
reproduction ratio R0 in models for infectious diseases. *J. Math. Biol.* **28**, 365-382 (1990).

24   Yang, J. *et al.* Disease burden and clinical severity of the first pandemic wave of COVID-
19 in Wuhan, China. *Nature Communications* **11**, 5411, doi:10.1038/s41467-020-19238-
2 (2020).

25   Halloran, M. E., Longini, I. M. & Struchiner, C. J. in *Design and Analysis of Vaccine Studies*
131-151 (Springer New York, 2010).

26   Yang, J. *et al.* Despite vaccination, China needs non-pharmaceutical interventions to
prevent widespread outbreaks of COVID-19 in 2021. *Nature Human Behaviour*,
doi:10.1038/s41562-021-01155-z (2021).

27   Mistry, D. *et al.* Inferring high-resolution human mixing patterns for disease modeling.
Nat Commun **12**, 323, doi:10.1038/s41467-020-20544-y (2021).

28   Hodgson, D., Flasche, S., Jit, M. & Kucharski, A. J. The potential for vaccination-induced
herd immunity against the SARS-CoV-2 B.1.1.7 variant. *Euro Surveill* **26**,
doi:10.2807/1560-7917.Es.2021.26.20.2100428 (2021).

29   Wang, J. *et al.* Acceptance of COVID-19 Vaccination during the COVID-19 Pandemic in
China. *Vaccines (Basel)* **8**, doi:10.3390/vaccines8030482 (2020).

30   Chen, M. *et al.* An online survey of the attitude and willingness of Chinese adults to
receive COVID-19 vaccination. *Hum Vaccin Immunother*, 1-10,
doi:10.1080/21645515.2020.1853449 (2021).

31   Wang, C. *et al.* Vaccination willingness, vaccine hesitancy, and estimated coverage at the
first round of COVID-19 vaccination in China: A national cross-sectional study. *Vaccine*
39, 2833-2842, doi:10.1016/j.vaccine.2021.04.020 (2021).

32   Gan, L. *et al.* Willingness to Receive SARS-CoV-2 Vaccination and Associated Factors
among Chinese Adults: A Cross Sectional Survey. *Int J Environ Res Public Health* **18**,
doi:10.3390/ijerph18041993 (2021).

33   Zhang, H. J. *et al.* Willingness to receive novel coronavirus vaccine and factors
influencing willingness among healthcare workers in Zhejiang province. *Chin J Vacc*
Immun (2021).

34   Lazarus, J. V. *et al.* A global survey of potential acceptance of a COVID-19 vaccine. *Nat*
Med **27**, 225-228, doi:10.1038/s41591-020-1124-9 (2021).

35   Carl A.B. Pearson, T. W. R., Nicholas Davies, Adam J Kucharski, CMMID COVID-19
working group, W John Edmunds & Rosalind M Eggo. Estimates of severity and
transmissibility of novel SARS-CoV-2 variant 501Y.V2 in South Africa.   (2021).
36   Washington, N. L. *et al.* Emergence and rapid transmission of SARS-CoV-2 B.1.1.7 in the
United States. *Cell* **184**, 2587-2594 e2587, doi:10.1016/j.cell.2021.03.052 (2021).
37   Graham, M. S. *et al.* Changes in symptomatology, reinfection, and transmissibility
associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. *Lancet Public*
Health **6**, e335-e345, doi:10.1016/S2468-2667(21)00055-4 (2021).
38   Challen, R. *et al.* Early epidemiological signatures of novel SARS-CoV-2 variants:
establishment of B.1.617.2 in England. *medRxiv*, 2021.2006.2005.21258365,
doi:10.1101/2021.06.05.21258365 (2021).
39   Dagpunar, J. Interim estimates of increased transmissibility, growth rate, and
reproduction number of the Covid-19 B.1.617.2 variant of concern in the United
Kingdom. *medRxiv*, 2021.2006.2003.21258293, doi:10.1101/2021.06.03.21258293 (2021).
40   Volz, E. *et al.* Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England.
Nature **593**, 266-269, doi:10.1038/s41586-021-03470-x (2021).
41   Davies, N. G. *et al.* Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7
in England. *Science* **372**, doi:10.1126/science.abg3055 (2021).
42   Faria, N. R. *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in
Manaus, Brazil. *Science* **372**, 815-821, doi:10.1126/science.abh2644 (2021).
43   Aguas, R. *et al.* Herd immunity thresholds for SARS-CoV-2 estimated from unfolding
epidemics. 2020.2007.2023.20160762, doi:10.1101/2020.07.23.20160762 %J medRxiv
(2020).
44   Kwok, K. O., Lai, F., Wei, W. I., Wong, S. Y. S. & Tang, J. W. T. Herd immunity - estimating
the level required to halt the COVID-19 epidemics in affected countries. *J Infect* **80**,
e32-e33, doi:10.1016/j.jinf.2020.03.027 (2020).
45   Omer, S. B., Yildirim, I. & Forman, H. P. Herd Immunity and Implications for SARS-CoV-2
Control. *JAMA* **324**, 2095-2096, doi:10.1001/jama.2020.20892 %J JAMA (2020).
46   Tetteh, J. N. A., Nguyen, V. K. & Hernandez-Vargas, E. A. COVID-19 Network Model to
Evaluate Vaccine Strategies towards Herd Immunity. *medRxiv*,
2020.2012.2022.20248693, doi:10.1101/2020.12.22.20248693 (2020).
47   Gomes, M. G. M. *et al.* Individual variation in susceptibility or exposure to SARS-CoV-2
lowers the herd immunity threshold. *medRxiv*, 2020.2004.2027.20081893,
doi:10.1101/2020.04.27.20081893 (2020).
48   Lu, D. *et al.* Data-driven estimate of SARS-CoV-2 herd immunity threshold in
populations with individual contact pattern variations. *medRxiv*,
2021.2003.2019.21253974, doi:10.1101/2021.03.19.21253974 (2021).
49   Centers for Disease Control and Prevention. Nationwide Commercial Laboratory
Seroprevalence Survey.   (2021).
50   Polack, F. P. *et al.* Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. *N Engl*
J Med **383**, 2603-2615, doi:10.1056/NEJMoa2034577 (2020).
51   Zhang, Y. *et al.* Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2
vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-
controlled, phase 1/2 clinical trial. *Lancet Infect Dis* **21**, 181-192, doi:10.1016/S1473-

666		3099(20)30843-4 (2021).
667	52	Wang, Z. *et al.* Naturally enhanced neutralizing breadth against SARS-CoV-2 one year
668		after infection. *Nature*, doi:10.1038/s41586-021-03696-9 (2021).
669	53	Manica, M. *et al.* The risk of symptomatic infection during a second COVID-19 wave, in
670		SARS-CoV-2 seropositive individuals. *Clinical Infectious Diseases*,
671		doi:10.1093/cid/ciab556 (2021).
672	54	Hall, V. *et al.* Do antibody positive healthcare workers have lower SARS-CoV-2 infection
673		rates than antibody negative healthcare workers? Large multi-centre prospective cohort
674		study (the SIREN study), England: June to November 2020. *medRxiv*,
675		2021.2001.2013.21249642, doi:10.1101/2021.01.13.21249642 (2021).
676	55	Lavine, J. S., Bjornstad, O. N. & Antia, R. Immunological characteristics govern the
677		transition of COVID-19 to endemicity. *Science* **371**, 741-745,
678		doi:10.1126/science.abe6522 (2021).
679	56	Saad-Roy, C. M. *et al.* Immune life history, vaccination, and the dynamics of SARS-CoV-
680		2 over the next 5 years. *Science* **370**, 811-818, doi:10.1126/science.abd7343 (2020).
681	57	National Medical Products Administration. *NMPA conditionally approves the registration*
682		*application of the inactivated COVID-19 vaccine (Vero cell) developed by State-owned*
683		*Sinopharm*, <https://www.nmpa.gov.cn/yaopin/ypjgdt/20201231193329157.html>
684		(2020).
685	58	National Medical Products Administration. *NMPA conditionally approves the registration*
686		*application of the inactivated COVID-19 vaccine (Vero cell) developed by Beijing-*
687		*based Sinovac Life Sciences Co Ltd*,
688		<https://www.nmpa.gov.cn/yaopin/ypjgdt/20210206154636109.html> (2021).
689	59	National Medical Products Administration. *NMPA conditionally approves the registration*
690		*application of the recombinant COVID-19 vaccine (adenovirus type-5-vectored vaccine)*
691		*developed by CanSino Biologics*,
692		<https://www.nmpa.gov.cn/yaowen/ypjgyw/20210225184523188.html> (2021).
693	60	National Medical Products Administration. *NMPA conditionally approves the registration*
694		*application of the inactivated COVID-19 vaccine (Vero cell) developed by the Wuhan*
695		*Institute of Biological Products administered by Sinopharm*,
696		<https://www.nmpa.gov.cn/yaowen/ypjgyw/20210225184306142.html> (2021).
697	61	Hu, S. *et al.* Infectivity, susceptibility, and risk factors associated with SARS-CoV-2
698		transmission under intensive contact tracing in Hunan, China. *Nat Commun* **12**, 1533,
699		doi:10.1038/s41467-021-21710-6 (2021).
700	62	Chinazzi, M. *et al.* The effect of travel restrictions on the spread of the 2019 novel
701		coronavirus (COVID-19) outbreak. *Science* **368**, 395-400, doi:10.1126/science.aba9757
702		(2020).
703	63	Pang, X. *et al.* Cold-chain food contamination as the possible origin of COVID-19
704		resurgence in Beijing. *National Science Review* **7**, 1861-1864, doi:10.1093/nsr/nwaa264
705		(2020).
706	64	The State Council Information Office of the People's Republic of China. *Press conference*
707		*held on China's COVID-19 vaccine*,
708		<http://www.gov.cn/xinwen/gwylflkjz143/index.htm> (2020).
709	65	National Health Commision of the People's Republic of China. *Update on the doses of*

710		*COVID-19 vaccine administration*, <http://www.nhc.gov.cn/xcs/yqjzqk/list_gzbd.shtml> (
711	66	SINOVAC. *Supply Vaccines to Eliminate Human Diseases.*,
712		<http://www.sinovac.com.cn/?optionid=468&auto_id=1877> (2021).
713	67	CanSinoBIO. *The application for conditional marketing of CansinoBio Coronavirus*
714		*Vaccine ConvideciaTM was accepted by the National Medical Products Administration.*,
715		<http://www.cansinotech.com.cn/html/1///179/180/806.html> (2021).
716	68	Beijing Institute of Biological Products Co. LTD. *Products Instruction*,
717		<https://www.bjbpi.com/?p=75> (2021).
718	69	Wuhan Institute of Biological Products Co. LTD. *The interim analysis data of the COVID-*
719		*19 inactivated vaccine phase III clinical trial of Sinopharm Wuhan Institute of Biological*
720		*Products released.*, <http://www.wibp.com.cn/Chs/Detail.aspx?Id=14669> (2021).
721	70	Palacios, R. *et al.* (SSRN, 2021).
722	71	Organization, W. H. Evidence Assessment: Sinovac/CoronaVac COVID-19 vaccine.
723		(2021).
724	72	Chen, X. *et al.* Serological evidence of human infection with SARS-CoV-2: a systematic
725		review and meta-analysis. *Lancet Glob Health* **9**, e598-e609, doi:10.1016/S2214-
726		109X(21)00026-7 (2021).
727	73	World Health Organization. *WHO situation report: Weekly epidemiological update on*
728		*COVID-19 - 1 June 2021*, <https://www.who.int/publications/m/item/weekly-*
729		epidemiological-update-on-covid-19---1-june-2021> (2021).
730	74	Davies, N. G. *et al.* Increased mortality in community-tested cases of SARS-CoV-2
731		lineage B.1.1.7. *Nature*, doi:10.1038/s41586-021-03426-1 (2021).
732	75	Challen, R. *et al.* Risk of mortality in patients infected with SARS-CoV-2 variant of
733		concern 202012/1: matched cohort study. *BMJ* **372**, n579, doi:10.1136/bmj.n579 (2021).

End notes

Acknowledgments

The study was supported by grants from the National Science Fund for Distinguished

Young Scholars (No. 81525023), European Union Grant 874850 MOOD (MOOD

000), and the National Institute for Health Research (NIHR) (grant no. 16/137/109)

using UK aid from the UK Government to support global health research. We also

acknowledge grant from Shanghai Key Laboratory of Infectious Diseases and

Biosafety Emergency Response (20dz2260100). The views expressed in this

publication are those of the author(s) and not necessarily those of the NIHR or the UK

Department of Health and Social Care.

Author Contributions

H.Y. conceived and designed the study. H.Y. and M.A. supervised the study. M.A.

designed the model. H.L. developed the model. H.L., J.Z., J.C., J.Y., X.D. analyzed

the model outputs. H.L., C.P., X.D, and Z.C. prepared the tables and figures. H.L. and

J.Z. prepared the first draft of the manuscript. W.Z. and Q.W. participated in data

collection. X.C and Z.C. updated the relative literatures. H.Y., M.A. W.Z. and C. V.

revised the content critically. All authors contributed to review and revision and

approved the final manuscript as submitted and agree to be accountable for all aspects

of the work.

Declaration of interests

H.Y. has received research funding from Sanofi Pasteur, GlaxoSmithKline, Yichang HEC Changjiang Pharmaceutical Company, and Shanghai Roche Pharmaceutical Company. M.A. has received research funding from Seqirus. None of those research funding is related to COVID-19. All other authors report no competing interests.

Disclaimer

This article does not necessarily represent the views of the NIH or the US government.